Why carry out this study?

Supplemental ceftaroline is an established option in the treatment of prolonged MRSA bacteremia refractory to vancomycin or daptomycin therapy.

The question of whether to continue with ceftaroline plus vancomycin or daptomycin following bacteremia resolution, however, remains unanswered.

In hopes of uncovering findings supporting a particular regimen, treatment outcomes were compared in patients prescribed vancomycin or daptomycin alone following bacteremia resolution versus patients who continued combination therapy.

What was learned from the study?

No statistically significant difference in inpatient mortality, recurrence of bacteremia, 30-day readmission, acute kidney injury, or leukopenia was seen in patients prescribed vancomycin or daptomycin alone following bacteremia resolution versus patients who continued combination therapy.

Considering treatment outcomes did not differ in patients prescribed vancomycin or daptomycin alone following bacteremia resolution, our finding encourages confining ceftaroline use to active bacteremia.